Group 1: AbbVie - AbbVie is recognized as a Dividend King, having increased its payouts for at least 50 consecutive years, indicating strong business stability [2] - The company has a diverse portfolio of medicines and a robust pipeline, which positions it well to maintain consistent revenue and earnings despite patent expirations [3] - AbbVie is expected to benefit from long-term trends such as the aging global population, which will increase demand for pharmaceutical products [6] Group 2: Mastercard - Mastercard has increased its dividend payouts by nearly 358% over the past decade, showcasing its strong business fundamentals [7] - The company processes credit and debit card transactions and is insulated from credit risk, allowing it to perform well even during economic downturns [8] - Mastercard has a significant addressable market, estimated at approximately $12.5 trillion, and is well-positioned to capitalize on the ongoing shift from cash to digital payments [10][11]

Core Viewpoint - AbbVie Inc. is considered one of the best healthcare stocks to buy for 2026, with Goldman Sachs reaffirming a Neutral rating and a price target of $223 ahead of its Q4 2025 earnings and 2026 guidance release [1] Financial Performance - Goldman Sachs projects AbbVie will achieve $67.1 billion in revenue for 2026, with $21.3 billion from Skyrizi and $10.4 billion from Rinvoq, alongside an EPS of $14.22, which aligns with consensus expectations [1] - A slight revenue beat is anticipated in Q4, driven by Skyrizi's performance exceeding expectations, while Rinvoq is expected to perform slightly below [2] Business Segments - The Aesthetics business is under continued pressure, while Neurology and Oncology are expected to show steady results [2] - AbbVie has a high P/E ratio of 168.95, reflecting strong growth expectations, supported by a dividend yield of 3.09% [2] Clinical Trials - AbbVie reported mixed results in the phase 3 Lymphoma trial for epcoritamab, showing improved progression-free survival but failing to meet the overall survival endpoint [3] - The adverse events observed were consistent with the known safety profile of the candidate drug [3] Strategic Response - AbbVie and its partner Genmab are investigating potential factors that may have negatively influenced the trial results, including the impact of the COVID-19 pandemic and the availability of new anti-lymphoma therapies [4] Company Overview - AbbVie is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for complex health issues, specializing in immunology, oncology, neuroscience, and eye care [5]

Core Viewpoint - AbbVie Inc. is recognized as one of the 12 best long-term stocks to buy, despite facing some challenges in clinical trials [1]. Group 1: Market Analysis - Citi has adjusted its price target for AbbVie to $230 from $235 while maintaining a Neutral rating, indicating a more supportive backdrop for the biopharma sector in 2026 due to manageable earnings expectations and reduced policy-related risks [2]. - The overall sentiment in the biopharma space suggests that earnings may exceed previous fears, contributing to a more favorable investment environment [2]. Group 2: Clinical Developments - AbbVie and Genmab's blood cancer drug, epcoritamab, did not demonstrate a statistically significant survival benefit in a late-stage study involving 483 patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - Despite the lack of clear survival benefits, the study revealed positive outcomes, such as a higher number of patients achieving undetectable cancer levels, longer response durations, and improved time before requiring further treatment [4]. - Epcoritamab is already approved in several countries for other lymphoma indications, marketed as Epkinly in the U.S. and Japan, and as Tepkinly in the European Union [5].

Core Insights - The article discusses the author's background in analytics and accounting, highlighting over 10 years of experience in the investment sector, progressing from an analyst to a management role [1]. Group 1 - The author holds a master's degree in Analytics from Northwestern University and a bachelor's degree in Accounting [1]. - The author has a personal interest in dividend investing and aims to share insights with the Seeking Alpha community [1]. Group 2 - The author has disclosed a beneficial long position in several companies, including ABBV, ADP, HRL, JNJ, LOW, PEP, and SPGI, through various financial instruments [2]. - The article emphasizes that the author's opinions are personal and not influenced by compensation from any company mentioned [2].

AbbVie (NYSE: ABBV) is one of the largest pharmaceutical companies in the world. Though its portfolio spans many therapeutic areas, it is particularly well known for its work in immunology, a field in which it boasts some of the best-selling therapies. However, many smaller drugmakers are trying to break into this space. One of them, Abivax (NASDAQ: ABVX), has grabbed quite a few headlines of late thanks to a potentially transformative immunology medicine still in development. Should investors opt for the ...

Core Viewpoint - Analysts expect AbbVie (ABBV) to report quarterly earnings of $2.66 per share, reflecting a year-over-year increase of 23.2%, with revenues projected at $16.36 billion, up 8.3% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical research showing a strong correlation between earnings estimate revisions and short-term stock performance [2] Revenue Projections - Analysts estimate 'Net Revenue- Imbruvica' at $714.90 million, indicating a year-over-year decline of 15.7% [4] - 'Net Revenue- Botox Therapeutic- Total' is expected to reach $995.91 million, reflecting a year-over-year increase of 14.1% [4] - 'Net Revenue- Venclexta' is projected at $725.34 million, suggesting a year-over-year increase of 10.7% [4] Neuroscience and Humira Revenue - 'Net Revenue- Neuroscience- Total' is estimated at $3.00 billion, indicating a year-over-year increase of 19.5% [5] - 'Net Revenue- Humira- US' is expected to be $574.85 million, reflecting a significant decline of 53.9% from the prior year [5] - 'Net Revenue- Humira- International' is projected at $374.40 million, indicating a year-over-year decrease of 14.1% [6] Oncology and New Products - 'Net Revenue- Oncology- Elahere- Total' is expected to reach $191.62 million, reflecting a year-over-year increase of 29.5% [6] - 'Net Revenue- Epkinly- International' is projected at $48.50 million, suggesting a substantial year-over-year increase of 120.5% [6] - 'Net Revenue- Qulipta- U.S.' is estimated at $271.58 million, indicating a year-over-year increase of 46% [7] - 'Net Revenue- Qulipta- International' stands at $39.74 million, reflecting a significant year-over-year increase of 165% [8] Stock Performance - AbbVie shares have decreased by 3.5% over the past month, contrasting with the Zacks S&P 500 composite's increase of 0.9%, and the stock is expected to closely follow the overall market with a Zacks Rank 3 (Hold) [8]

Group 1 - The article highlights the significant rise in investment returns, particularly in AI and tech stocks, which saw triple-digit growth in 2025 [1] - The author, Rick, has over 20 years of experience in trading stocks and options, and his work is recognized by major publications [1] - Rick's book, "The Financially Independent Millennial," aims to inspire readers by sharing his journey to financial independence at age 35 [1] Group 2 - The article does not provide any specific investment recommendations or advice regarding the suitability of investments for particular investors [2][3] - There is a clear disclaimer that past performance does not guarantee future results, emphasizing the speculative nature of investments [3]

Group 1 - Major reports are expected from Mastercard Incorporated, Caterpillar Inc., and SAP SE before the market opens on Thursday [1] - Tech companies Apple Inc. and Visa Inc. will report their earnings after the market closes on Thursday [1] - Energy companies Exxon Mobil Corporation and Chevron Corporation are set to report before the market opens on Friday [1] Group 2 - A busy day for healthcare reporting is anticipated next Wednesday, with Eli Lilly and Company, AbbVie Inc., Novartis AG, and Novo Nordisk A/S scheduled to release their earnings [1] - Alphabet Inc. will report its earnings after the market closes on the same day [1] - The week will conclude with Amazon.com Inc. reporting after the market closes next Thursday [1]

Core Viewpoint - AbbVie had a remarkable year in 2025, with its stock price increasing by nearly 29%, outperforming the S&P 500 index's 16% gain, driven by strong sales from its leading drugs and strategic acquisitions [1][2]. Group 1: Sales Performance - AbbVie successfully navigated the patent cliff of its popular drug Humira, with its two leading drugs, Skyrizi and Rinvoq, generating a combined $24 billion in sales during the year, surpassing the total revenue of most pharmaceutical companies [2][3]. - The immunology segment, which includes Humira, Skyrizi, and Rinvoq, is not the only growth driver; the neuroscience segment also performed well, with Vyralar achieving a nearly 7% year-over-year sales increase to $931 million in Q3 2025 [4]. Group 2: Strategic Growth Initiatives - AbbVie actively pursued acquisitions and collaborations to sustain growth, including the notable acquisition of Capstan Therapeutics, which focuses on next-generation autoimmune therapies [5][6]. - The company entered into a partnership with China's Simcere Zaiming for an investigational multiple myeloma drug, highlighting its commitment to expanding its pipeline through strategic alliances [6]. Group 3: Future Outlook - Although AbbVie has not yet released its Q4 and full-year 2025 results, both the company and analysts anticipate an annual revenue increase of over 8% to nearly $61 billion, despite a projected 2% dip in per-share profitability to $9.93 [7].

Core Viewpoint - AbbVie (ABBV) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings expected to be $3.02 per share, reflecting a +39.8% change, and revenues projected at $16.38 billion, up 8.5% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 4, and the stock may rise if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 0.32% higher in the last 30 days, indicating a slight positive adjustment from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that AbbVie has a negative Earnings ESP of -12.44%, suggesting analysts have become bearish on the company's earnings prospects [12]. - Despite the negative Earnings ESP, AbbVie holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - AbbVie has a history of beating consensus EPS estimates, having done so in the last four quarters, with a recent surprise of +5.08% when it reported earnings of $1.86 per share against an expectation of $1.77 [13][14]. Industry Context - In the broader pharmaceutical industry, Merck (MRK) is also expected to report earnings of $2.04 per share for the same quarter, reflecting a year-over-year change of +18.6%, with revenues projected at $16.19 billion, up 3.6% [18]. - Merck's consensus EPS estimate has been revised down by 85.2% over the last 30 days, and it currently has an Earnings ESP of +0.33% but holds a Zacks Rank of 4, complicating predictions for an earnings beat [19][20].